CClinicalTrials.gg
CompletedNCT07582692NFB-AUDUpdated May 13, 2026

Sequential Prefrontal Alpha-Theta Neurofeedback on Abstinence Self-Efficacy, Mindfulness, and EEG in Alcohol Use Disorder

An interventional study of Sequential Prefrontal Alpha-Theta Neurofeedback Training in Alcohol Use Disorder, sponsored by Seoul University of Buddhism. Completed at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Seoul University of Buddhism · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jul 2024, registered May 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study examined the effects of sequential prefrontal alpha-theta neurofeedback training on abstinence self-efficacy, mindfulness, and brain electroencephalography (EEG) activity in adults with Alcohol Use Disorder (AUD). Participants in the experimental group received 24 sessions of neurofeedback over 8 weeks (3 sessions per week, 30 minutes per session), while a control group received no intervention. EEG and self-report measures were assessed at baseline and post-intervention.

02

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • neurofeedback
  • EEG
  • abstinence self-efficacy
  • mindfulness
  • alpha-theta
03

In context

Alcoholism

1,606 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's enrollment of 17 is below the median of 87 across 1,371 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

This is the only study on the registry with Seoul University of Buddhism as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adults diagnosed with Alcohol Use Disorder (AUD) according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria
  2. Alcohol Use Disorders Identification Test-Korean (AUDIT-K) score >= 20 (males) or >= 10 (females) indicating high-risk drinking
  3. Voluntary written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Sensory impairment (visual or auditory)
  2. Diagnosis of intellectual disability
  3. Current use of antipsychotics, central nervous system stimulants, or sedatives
  4. Active neurological conditions (e.g., epilepsy, recent traumatic brain injury)
  5. Severe psychiatric comorbidities (e.g., active psychosis) contraindicated for EEG-based neurofeedback
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Sequential Prefrontal Alpha-Theta Neurofeedback

    24 sessions of sequential prefrontal alpha-theta neurofeedback training over 8 weeks (3 sessions/week, 30 min/session). Each session: 5 min alpha feedback (8-12 hertz \[Hz\]) followed by 25 min theta feedback (4-7 Hz) at Fp1/Fp2, delivered via ocean wave and birdsong audio while eyes closed. Device: Power Nap (Neuro21, Korea).

    Behavioral: Sequential Prefrontal Alpha-Theta Neurofeedback Training

  • No intervention
    Control - No Intervention

    Participants continued usual daily activities for 8 weeks without any intervention. Pre- and post-test assessments (EEG and self-report measures) were conducted.

Interventions

  • BehavioralSequential Prefrontal Alpha-Theta Neurofeedback Training

    Operant conditioning-based neurofeedback: 5 min alpha (8-12 Hz) + 25 min theta (4-7 Hz) at prefrontal sites Fp1/Fp2 per session; 24 sessions over 8 weeks supervised by a certified practitioner. Audio feedback (ocean waves for alpha, birdsong for theta) delivered via Power Nap device (Neuro21, Korea) while participants remained eyes-closed and seated.

06

What researchers measure

Primary outcomes

  1. Abstinence Self-Efficacy

    Total score on the Alcohol Abstinence Self-Efficacy Scale (AASE; Korean adaptation), a 20-item scale with four subscales (Negative Affect, Social/Positive Emotions, Physical and Other Concerns, Withdrawal and Urges), each rated 0-4; higher scores indicate greater confidence in maintaining abstinence.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

Secondary outcomes

  1. Mindfulness

    Total score on the Mindfulness Scale (20 items, 4 subscales: Decentered Attention, Nonjudgmental Acceptance, Present-Moment Awareness, Attentional Focus), rated 1-5 (reverse-scored); higher scores indicate greater mindfulness.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

  2. EEG Relative Power

    Relative spectral power (% of total power) across delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta (13-30 Hz), and sensorimotor rhythm (SMR; 12-15 Hz) bands at prefrontal sites (Fp1, Fp2), measured using eyes-closed resting EEG with the NeuroBrain system.

    Time frame: Baseline (Week 0) and post-intervention (Week 8)

07

Study locations

1 site
  • Neurofeedback Training Centre
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07582692
Lead sponsor
Seoul University of Buddhism
Responsible party
Yerin Hong (Principal Investigator, Seoul University of Buddhism) — Principal investigator
First posted
May 13, 2026
Start date
Jul 1, 2024
Primary completion
Sep 25, 2024
Completion
Sep 25, 2024
Last update
May 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion